The Illumina mission is to improve human health by unlocking the power of the genome. Now, through innovation and collaboration, we are enabling genomic breakthroughs in Oncology. The opportunity to change tumor profiling with innovative assays that enable comprehensive genomic profiling, new companion diagnostic development, and liquid biopsy inspires us to push boundaries of precision medicine and drive innovation.
Comprehensive genomic profiling (CGP) is a next-generation sequencing (NGS) approach that uses a single assay to assess hundreds of genes including relevant cancer biomarkers, as established in guidelines and clinical trials, for therapy guidance.
Download of the brochures by clicking on the picture.